Compare

Bure Equity AB/Skr BURE

1D1W1M3M6MYTD1Y5YMAX

About Bure Equity AB

Bure Equity AB is an investment company based in Stockholm, Sweden, focusing on long-term ownership of companies with strong growth potential. The firm engages in the acquisition, development, and management of a diverse portfolio, encompassing sectors like technology, healthcare, industrials, and financial services. Founded in 1992, Bure Equity operates by actively supporting the strategic efforts of its portfolio companies to enhance value and growth. With a strong presence primarily in the Nordic region, the company leverages its expertise in governance and industry knowledge to drive successful outcomes. Bure Equity's strategic approach emphasizes long-term value creation and active involvement in its investments.
Ticker
Skr BURE
Sector
Finance
Primary listing
XSTO
Employees
12
Headquarters
Stockholm, Sweden
Website
www.bure.se/en/home-en

Bure Equity AB Metrics

BasicAdvanced
kr 23B
4.52
kr 67.66
1.29
kr 2.75
0.90%

Bulls say / Bears say

Bure’s net asset value per share rose 28.4% in the first half of 2026 to SEK 342.9, ahead of the SIX Return Index’s 8.1% gain. That is a strong recovery and suggests its portfolio has regained momentum. (Bure Equity AB)
Mycronic’s operating outlook strengthened: all divisions reported better order intake and the board raised its full-year sales forecast. As Bure’s largest holding, continued delivery could materially support its value. (Bure Equity AB)
Silex’s IPO gives investors a listed valuation for a major Bure holding and has opened up opportunities for global expansion. By the end of June, Silex had gained 148% from its listing price and Bure’s stake value had risen from SEK 900 million to SEK 3.3 billion. (Bure Equity AB)
The first quarter showed how sharply Bure’s value can swing: NAV per share fell 9%, while its share’s total return was -11.8%, against a 1.2% fall in the SIX Return Index. The subsequent recovery does not remove that volatility risk. (Bure Equity AB)
Several holdings had serious setbacks in the first quarter: Yubico’s share price fell 54.4%, Vitrolife’s fell 31.2%, and Bure wrote down its Mentimeter holding by SEK 173 million. This highlights the risk that weakness across individual investments can weigh on the portfolio. (Bure Equity AB)
Bure’s exposure is concentrated in Mycronic, which accounted for more than half of its net asset value in April. Strong performance there helps Bure, but a setback at one company could have an outsized effect on the investment firm. (EFN)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.

Bure Equity AB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Funds containing Bure Equity AB

AllUSDEURGBP
Funds
Fund name
Fund size
Skr BURE weighting
iShares Listed Private Equity$IDPE
$843M0.61%
iShares Listed Private Equity£IPRV
$843M0.61%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.11%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.11%
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.